STOCK TITAN

Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
AI

Revvity, Inc. (NYSE: RVTY) has launched Revvity Transcribe AI, an innovative optical character recognition (OCR) service that converts handwritten text on test request forms into digital format. This solution aims to streamline workflows and reduce manual data entry tasks in clinical laboratories. Key features include:

  • 40% improvement in overall data entry workflow speed, including data validation
  • Especially valuable for newborn screening (NBS) laboratories
  • Compatible with Revvity's EVOYA™ platform for NBS software
  • Secure data processing with ISO27001 compliance

The service allows laboratory personnel to focus on other essential tasks by automating the manually intensive process of transcribing handwritten information. Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium in Omaha, Nebraska.

Revvity, Inc. (NYSE: RVTY) ha lanciato Revvity Transcribe AI, un innovativo servizio di riconoscimento ottico dei caratteri (OCR) che converte il testo scritto a mano sui moduli di richiesta di test in formato digitale. Questa soluzione mira a semplificare i flussi di lavoro e a ridurre le attività di immissione manuale dei dati nei laboratori clinici. Caratteristiche principali includono:

  • un miglioramento del 40% nella velocità complessiva del flusso di lavoro di immissione dei dati, compresa la convalida dei dati
  • particolarmente prezioso per i laboratori di screening dei neonati (NBS)
  • compatibile con la piattaforma EVOYA™ di Revvity per il software NBS
  • elaborazione sicura dei dati con conformità ISO27001

Il servizio consente al personale di laboratorio di concentrarsi su altre attività essenziali automatizzando il processo laborioso di trascrizione delle informazioni scritte a mano. Revvity Transcribe AI sarà presentato al Simposio sullo Screening dei Neonati dell'APHL 2024 a Omaha, Nebraska.

Revvity, Inc. (NYSE: RVTY) ha lanzado Revvity Transcribe AI, un innovador servicio de reconocimiento óptico de caracteres (OCR) que convierte el texto manuscrito en formularios de solicitud de pruebas a formato digital. Esta solución tiene como objetivo optimizar los flujos de trabajo y reducir las tareas de entrada manual de datos en laboratorios clínicos. Las características clave incluyen:

  • mejora del 40% en la velocidad general del flujo de trabajo de entrada de datos, incluida la validación de datos
  • especialmente valioso para los laboratorios de cribado neonatal (NBS)
  • compatible con la plataforma EVOYA™ de Revvity para software NBS
  • procesamiento de datos seguro con cumplimiento de ISO27001

El servicio permite al personal del laboratorio enfocarse en otras tareas esenciales al automatizar el proceso manualmente intensivo de transcripción de información manuscrita. Revvity Transcribe AI se presentará en el Simposio de Cribado Neonatal APHL 2024 en Omaha, Nebraska.

Revvity, Inc. (NYSE: RVTY)는 Revvity Transcribe AI를 출시했습니다. 이는 테스트 요청 양식에 손으로 쓴 텍스트를 디지털 형식으로 변환하는 혁신적인 광학 문자 인식(OCR) 서비스입니다. 이 솔루션은 임상 실험실에서 작업 흐름을 간소화하고 수동 데이터 입력 작업을 줄이는 것을 목표로 합니다. 주요 기능은 다음과 같습니다:

  • 데이터 검증을 포함하여 전체 데이터 입력 작업 흐름 속도를 40% 향상
  • 신생아 스크리닝(NBS) 실험실에 특히 유용
  • NBS 소프트웨어를 위한 Revvity의 EVOYA™ 플랫폼과 호환
  • ISO27001 인증을 통한 안전한 데이터 처리

이 서비스는 연구원들이 수동으로 진행되는 손글씨 정보를 전사하는 작업을 자동화하여 다른 필수 작업에 집중할 수 있도록 합니다. Revvity Transcribe AI는 2024 APHL 신생아 스크리닝 심포지엄에서 네브래스카주 오마하에서 소개될 예정입니다.

Revvity, Inc. (NYSE: RVTY) a lancé Revvity Transcribe AI, un service innovant de reconnaissance optique de caractères (OCR) qui convertit le texte manuscrit sur les formulaires de demande de test en format numérique. Cette solution vise à rationaliser les flux de travail et à réduire les tâches de saisie manuelle des données dans les laboratoires cliniques. Les principales caractéristiques incluent :

  • une amélioration de 40 % de la vitesse globale du flux de travail de saisie des données, y compris la validation des données
  • particulièrement précieux pour les laboratoires de dépistage des nouveau-nés (NBS)
  • compatible avec la plateforme EVOYA™ de Revvity pour le logiciel NBS
  • traitement sécurisé des données avec conformité ISO27001

Le service permet au personnel de laboratoire de se concentrer sur d'autres tâches essentielles en automatisant le processus manuellement intensif de transcription des informations manuscrites. Revvity Transcribe AI sera présenté au Symposium APHL sur le dépistage des nouveau-nés 2024 à Omaha, Nebraska.

Revvity, Inc. (NYSE: RVTY) hat Revvity Transcribe AI eingeführt, einen innovativen Dienst zur optischen Zeichenerkennung (OCR), der handschriftlichen Text auf Testantragsformularen in ein digitales Format umwandelt. Diese Lösung zielt darauf ab, Arbeitsabläufe zu optimieren und manuelle Dateneingaben in klinischen Laboren zu reduzieren. Die wichtigsten Funktionen sind:

  • 40% Verbesserung der allgemeinen Geschwindigkeit des Dateneingabe-Workflows, einschließlich Datenvalidierung
  • Besonders wertvoll für Neugeborenenscreening (NBS)-Labore
  • Kompatibel mit Revvitys EVOYA™-Plattform für NBS-Software
  • Datensicherheit mit ISO27001-Konformität

Der Dienst ermöglicht es dem Laborpersonal, sich auf andere wesentliche Aufgaben zu konzentrieren, indem der manuelle, arbeitintensive Prozess der Transkription handschriftlicher Informationen automatisiert wird. Revvity Transcribe AI wird beim APHL Neugeborenenscreening-Symposium 2024 in Omaha, Nebraska, vorgestellt.

Positive
  • Improves data entry workflow speed by 40%, including data validation
  • Reduces manual data entry tasks, allowing staff to focus on other essential work
  • Compatible with existing Revvity EVOYA™ platform for newborn screening
  • Offers secure data processing with ISO27001 compliance
Negative
  • None.

Insights

Revvity's Transcribe AI represents a significant advancement in laboratory automation, addressing a critical pain point in clinical workflows. The 40% improvement in data entry speed is substantial, potentially translating to increased throughput and reduced operational costs for labs. This AI-driven OCR solution is particularly valuable for newborn screening labs, where speed and accuracy are paramount.

The integration with the EVOYA™ platform enhances its utility, offering a seamless workflow for NBS laboratories. The ISO27001 compliance ensures data security, a important factor in handling sensitive medical information. While the immediate impact is on efficiency, the long-term implications could include improved patient care through faster test processing and reduced human errors.

For investors, this product launch signals Revvity's commitment to innovation in the growing field of laboratory automation. It positions the company competitively in the $15.3 billion global lab automation market, which is expected to grow at a CAGR of 8.1% through 2030. The focus on newborn screening also taps into a niche but critical healthcare segment with stable demand.

Revvity's Transcribe AI launch is strategically timed to address the growing demand for efficiency in clinical laboratories. The global clinical laboratory services market, valued at $256.0 billion in 2022, is projected to reach $476.8 billion by 2030, with a CAGR of 7.2%. This growth is driven by increasing disease prevalence and the need for early diagnosis, areas where Transcribe AI can make a significant impact.

The product's focus on newborn screening is particularly astute. The global newborn screening market is expected to reach $2.5 billion by 2027, growing at a CAGR of 10.5%. By targeting this segment, Revvity is positioning itself in a high-growth, high-impact area of healthcare.

For investors, this launch represents a potential new revenue stream and a strengthening of Revvity's market position. The company's ability to innovate in AI and automation could lead to increased market share and improved financial performance in the medium to long term.

  • Enables transcription of handwritten test request forms to digitized format
  • Utilizes innovative AI for higher accuracy and efficiency
  • Data is securely processed with ISO27001 compliant solution

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This cutting-edge solution is now available to clinical laboratories, aiming to streamline workflows and reduce manual data entry tasks.

Revvity Transcribe AI addresses the need for laboratories to quickly and accurately process test request forms. In many laboratories, this is manual work that is time-consuming, prone to errors, and for which talent is hard to recruit. Based on initial internal data, the solution improves overall data entry workflow speed by 40 percent, including data validation.

While beneficial for a range of applications, this service is especially valuable for newborn screening (NBS) laboratories and is compatible with the EVOYA™ platform, Revvity’s NBS software solution. Public screening labs process hundreds of handwritten dried blood spot (DBS) test cards every day, and by deploying Revvity Transcribe AI, the manual data entry resource can instead be made available for other tasks within the laboratory.

“With the new Revvity Transcribe AI solution, labs can swiftly transcribe handwritten information on test request forms such as DBS filter paper cards using advanced AI-supported OCR technology,” said Norm Lord, vice president of digital products at Revvity. “This innovative service ensures that the digitized data is securely processed and seamlessly integrated into laboratory information management systems for review and verification. By automating this manually intensive process, Revvity Transcribe AI allows laboratory personnel to concentrate on other essential and time-sensitive tasks.”

Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium, October 20-24, in Omaha, Nebraska.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity

FAQ

What is Revvity Transcribe AI and how does it benefit clinical laboratories?

Revvity Transcribe AI is an optical character recognition (OCR) service that converts handwritten text on test request forms into digital format. It benefits clinical laboratories by improving data entry workflow speed by 40%, reducing manual tasks, and allowing staff to focus on other essential work.

How does Revvity Transcribe AI (RVTY) impact newborn screening laboratories?

Revvity Transcribe AI is especially valuable for newborn screening (NBS) laboratories, as it can process hundreds of handwritten dried blood spot (DBS) test cards daily, automating the manual data entry process and freeing up resources for other tasks within the laboratory.

Is Revvity Transcribe AI (RVTY) compatible with existing laboratory systems?

Yes, Revvity Transcribe AI is compatible with the EVOYA™ platform, Revvity's newborn screening software solution. It can also integrate seamlessly with laboratory information management systems for review and verification of digitized data.

When and where will Revvity Transcribe AI (RVTY) be introduced to the public?

Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium, taking place from October 20-24 in Omaha, Nebraska.

Revvity, Inc.

NYSE:RVTY

RVTY Rankings

RVTY Latest News

RVTY Stock Data

13.47B
121.36M
0.29%
91.94%
3.44%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
WALTHAM